by Kenneth Weinberg, Bruce R. Blazar, John E

Slides:

Advertisements

Similar presentations

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

Advertisements

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning Jamie H. Zao, Tal Schechter, Wenchao Jessica.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study by Pier M. Mannucci,

Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters by Maha El-Zimaity, Rima Saliba, Kawah Chan, Munir Shahjahan,

Gupta V, Tallman MS, Weisdorf DJ

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase by Jiří Pavlů,

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population by Sumithira Vasu,

Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine,

Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

Graph (box plots) shows primary tumor volumes of oral and maxillary sinus (A) and pharyngeal (B) cancers categorized at T1–T4. Graph (box plots) shows.

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Box-And-Whisker Plots

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD by Nelli Bejanyan, Claudio G. Brunstein,

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning Jamie H. Zao, Tal Schechter, Wenchao Jessica.

Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal.

Chronic Kidney Dysfunction in Patients Alive without Relapse 2 Years after Allogeneic Hematopoietic Stem Cell Transplantation Imad Abboud, Raphaël Porcher,

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Intensity of statistical methods and reporting subdivided by the journal groups. Intensity of statistical methods and reporting subdivided by the journal.

Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell Doses Seitaro Terakura, Eiichi.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients Pooja Khandelwal, Sabine Mellor-Heineke, Najibah.

An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes Julie A. Ross, Jakub Tolar, Logan G. Spector,

Efficacy of CD34+ Stem Cell Dose in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation after Total Body Irradiation Anurag K.

Box-And-Whisker Plots

Simon W. Rabkin et al. JACEP 2017;3:

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease by Jennifer S. Whangbo, Haesook.

Biology of Blood and Marrow Transplantation

Karen K. Ballen, Roberta J. King, Pintip Chitphakdithai, Charles D

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Box plots showing the relative difference in distribution of mtDNA copy number per cell between patients with ESRD and healthy control subjects frequency.

Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients by Jenna Sopfe, Laura Pyle, Amy K.

Bridge to transplant following Bv+Bs regimen.

Box plot of acquisition times across the various study cohorts.

Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H

William Berquist, MD Gastrointestinal Endoscopy

by Andrew L. Gilman, Michael J

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Sodium consumption (mg/day) at baseline by demographic characteristics in a cohort of self-referred patients with type 2 diabetes. Sodium consumption (mg/day)

Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

One-year costs by evaluation strategy.

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease by Paula Rodriguez-Otero,

Generation of Functional Thymocytes in the Human Adult

Mean nasopharyngeal pressure during high-flow oxygen therapy, with mouth open or closed. Mean nasopharyngeal pressure during high-flow oxygen therapy,

Presentation transcript:

Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation by Kenneth Weinberg, Bruce R. Blazar, John E. Wagner, Edward Agura, Brenna J. Hill, Monika Smogorzewska, Richard A. Koup, Michael R. Betts, Robert H. Collins, and Daniel C. Douek Blood Volume 97(5):1458-1466 March 1, 2001 ©2001 by American Society of Hematology

Cross-sectional analysis of TREC levels in relationship to GVHD Cross-sectional analysis of TREC levels in relationship to GVHD.(A) Individual CD4+ (●) and CD8+ (○) T-cell TREC levels are shown for a cross-section of patients through 25 years of age with no history of GVHD. (B) Patients through 25 years of age with chro... Cross-sectional analysis of TREC levels in relationship to GVHD.(A) Individual CD4+ (●) and CD8+ (○) T-cell TREC levels are shown for a cross-section of patients through 25 years of age with no history of GVHD. (B) Patients through 25 years of age with chronic GVHD. (C) Patients through 25 years of age with a history of GVHD. (D) A composite box plot for TREC levels is shown for all 3 groups. The top, bottom, and line through the middle of the box correspond to the 75th, 25th, and 50th percentile (median) respectively. The whiskers on the bottom and top extend from the 10th percentile and top 90th percentile, respectively. (E) Individual CD4+ (closed symbols) and CD8+ (open symbols) T-cell TREC levels are shown for a cross-section of patients older than 25 years of age with no history of GVHD (squares), with chronic GVHD (triangles), and with a history of GVHD (circles). Normal range of TREC levels for individuals of ages in groups studied are shown lying between the dashed lines. Kenneth Weinberg et al. Blood 2001;97:1458-1466 ©2001 by American Society of Hematology

TREC levels in a cohort of prospectively evaluated pediatric patients undergoing CBC transplantation.Individual CD4+ (●) and CD8+ (○) T-cell TREC levels are shown for patients at time points after undergoing CBC transplantation. TREC levels in a cohort of prospectively evaluated pediatric patients undergoing CBC transplantation.Individual CD4+ (●) and CD8+ (○) T-cell TREC levels are shown for patients at time points after undergoing CBC transplantation. Normal TREC levels for age are shown by the dashed line. Duration of immunosuppressive therapy is shown for cyclosporine (C), methylprednisolone (M), and ATG (A). Recorded instances of active GVHD (+) and no active GVHD (−) are also shown. The patients are identified by a letter followed by their age, and whether they had related CBC (RCB) or unrelated CBC (UCB) in the upper right of each plot. Patients E2, F7, and I8 all had increases in TREC levels while on immunosuppression. Kenneth Weinberg et al. Blood 2001;97:1458-1466 ©2001 by American Society of Hematology